1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: AI in Predictive Toxicology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. AI in Predictive Toxicology Market, by Technology
8.1.1. Classical Machine Learning
8.1.1.1. Market Revenue and Forecast
8.1.2. Deep Learning
8.1.2.1. Market Revenue and Forecast
8.1.3. Physics-Based & Molecular Modelling
8.1.3.1. Market Revenue and Forecast
8.1.4. Others (Hybrid AI, Knowledge Graphs, Generative AI)
8.1.4.1. Market Revenue and Forecast
9.1. AI in Predictive Toxicology Market, by Toxicity Endpoint
9.1.1. Systemic Toxicity
9.1.1.1. Market Revenue and Forecast
9.1.2. Hepatotoxicity
9.1.2.1. Market Revenue and Forecast
9.1.3. Cardiotoxicity
9.1.3.1. Market Revenue and Forecast
9.1.4. Neurotoxicity
9.1.4.1. Market Revenue and Forecast
10.1. AI in Predictive Toxicology Market, by Deployment Model
10.1.1. On-Premises Platforms
10.1.1.1. Market Revenue and Forecast
10.1.2. Cloud-Based Platforms
10.1.2.1. Market Revenue and Forecast
11.1. AI in Predictive Toxicology Market, by End User
11.1.1. Pharmaceutical & Biotechnology Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Research Organizations (CROs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Chemical & Cosmetics Companies
11.1.3.1. Market Revenue and Forecast
11.1.4. Academic & Research Institutes
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technology
12.1.2. Market Revenue and Forecast, by Toxicity Endpoint
12.1.3. Market Revenue and Forecast, by Deployment Model
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technology
12.1.5.2. Market Revenue and Forecast, by Toxicity Endpoint
12.1.5.3. Market Revenue and Forecast, by Deployment Model
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technology
12.1.6.2. Market Revenue and Forecast, by Toxicity Endpoint
12.1.6.3. Market Revenue and Forecast, by Deployment Model
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technology
12.2.2. Market Revenue and Forecast, by Toxicity Endpoint
12.2.3. Market Revenue and Forecast, by Deployment Model
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technology
12.2.5.2. Market Revenue and Forecast, by Toxicity Endpoint
12.2.5.3. Market Revenue and Forecast, by Deployment Model
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technology
12.2.6.2. Market Revenue and Forecast, by Toxicity Endpoint
12.2.6.3. Market Revenue and Forecast, by Deployment Model
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technology
12.2.7.2. Market Revenue and Forecast, by Toxicity Endpoint
12.2.7.3. Market Revenue and Forecast, by Deployment Model
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technology
12.2.8.2. Market Revenue and Forecast, by Toxicity Endpoint
12.2.8.3. Market Revenue and Forecast, by Deployment Model
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technology
12.3.2. Market Revenue and Forecast, by Toxicity Endpoint
12.3.3. Market Revenue and Forecast, by Deployment Model
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technology
12.3.5.2. Market Revenue and Forecast, by Toxicity Endpoint
12.3.5.3. Market Revenue and Forecast, by Deployment Model
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technology
12.3.6.2. Market Revenue and Forecast, by Toxicity Endpoint
12.3.6.3. Market Revenue and Forecast, by Deployment Model
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technology
12.3.7.2. Market Revenue and Forecast, by Toxicity Endpoint
12.3.7.3. Market Revenue and Forecast, by Deployment Model
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technology
12.3.8.2. Market Revenue and Forecast, by Toxicity Endpoint
12.3.8.3. Market Revenue and Forecast, by Deployment Model
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technology
12.4.2. Market Revenue and Forecast, by Toxicity Endpoint
12.4.3. Market Revenue and Forecast, by Deployment Model
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technology
12.4.5.2. Market Revenue and Forecast, by Toxicity Endpoint
12.4.5.3. Market Revenue and Forecast, by Deployment Model
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technology
12.4.6.2. Market Revenue and Forecast, by Toxicity Endpoint
12.4.6.3. Market Revenue and Forecast, by Deployment Model
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technology
12.4.7.2. Market Revenue and Forecast, by Toxicity Endpoint
12.4.7.3. Market Revenue and Forecast, by Deployment Model
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technology
12.4.8.2. Market Revenue and Forecast, by Toxicity Endpoint
12.4.8.3. Market Revenue and Forecast, by Deployment Model
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technology
12.5.2. Market Revenue and Forecast, by Toxicity Endpoint
12.5.3. Market Revenue and Forecast, by Deployment Model
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technology
12.5.5.2. Market Revenue and Forecast, by Toxicity Endpoint
12.5.5.3. Market Revenue and Forecast, by Deployment Model
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technology
12.5.6.2. Market Revenue and Forecast, by Toxicity Endpoint
12.5.6.3. Market Revenue and Forecast, by Deployment Model
12.5.6.4. Market Revenue and Forecast, by End User
13.1. Schrödinger
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Certara
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Simulations Plus
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Dassault Systèmes BIOVIA
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Charles River Laboratories
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Clarivate
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Insilico Medicine
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Exscientia
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Benevolent AI
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Recursion Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
